Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
5306 Views
Dr KK Aggarwal 20 May 2019
An international panel of experts has concluded that patients with subclinical hypothyroidism should not be routinely offered thyroid hormone replacement therapy.
In the recommendations published online this week in the BMJ, the expert panel writes “for adults with subclinical hypothyroidism, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid-related symptoms, including depressive symptoms, fatigue, and body mass index (BMI).”
The guidance, based on findings from a systematic review and meta-analysis of 21 trials with 2192 participants published in November (JAMA. 2018;320:1349-1359) represents a “strong recommendation” against prescribing thyroid hormones (primarily levothyroxine LT4) in adults with subclinical hypothyroidism.
Subclinical hypothyroidism is defined as elevated thyroid stimulating hormone (TSH) levels when free T4 (thyroxine) levels are normal.
(Source: Medscape)
Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}